Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104855 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL1521155 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL284741 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL7549072 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL9208454 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL24021536 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL7550356 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL7549080 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL1521609 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT | |
| SCHEMBL7545194 | 0.81 | L3MBTL1 (0.46) | L3MBTL1GAATYRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378408-A1 | NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF | BAR ILAN UNIVERSITY AN ISRAELI UNIVERSITY (IL) | 2014-12-25 | — | — | US | disclosed |
| US-20140378408-A1 | NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF | BAR ILAN UNIVERSITY AN ISRAELI UNIVERSITY (IL) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378408-A1 | NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF | CCL2, NUDT1, CXCL12 | L3MBTL1 3412/4885GAA 3236/4885TYR 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.